![[U.S. Food and Drug Administration]](https://webarchive.library.unt.edu/eot2008/20090119230402im_/http://www.fda.gov/icon/header.gif)
FDA Medical Bulletin * October 1996 * Volume 26
Number 3
TREATMENT INDS
The Treatment IND (investigational new drug) protocol is a mechanism that permits the use of certain investigational products to treat patients with serious or life-threatening diseases for which there are no satisfactory alternative treatments. For further information on the availability of the drug designated for Treatment IND status since June 1996, contact the product sponsor listed below:
Myotrophin: For treatment of amyotrophic lateral sclerosis. Cephalon, Inc., 1-800-829-3054.
REPORT SERIOUS ADVERSE EVENTS AND PRODUCT PROBLEMS TO
MEDWATCH
1-800-FDA-1088
![[Table of Contents]](https://webarchive.library.unt.edu/eot2008/20090119230402im_/http://www.fda.gov/icon/toc.gif)
![[FDA HOME PAGE]](https://webarchive.library.unt.edu/eot2008/20090119230402im_/http://www.fda.gov/icon/iconhome.gif)